-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WMJpR4BIrlSl+8oPyXR2oCV0bYyQWqJqM/tOw0hxqED6QGMRv6s/XfwfUFbEl6Pi
 VQ9I1moMDIp5XvcT3a23XQ==

<SEC-DOCUMENT>0001130319-06-000498.txt : 20060620
<SEC-HEADER>0001130319-06-000498.hdr.sgml : 20060620
<ACCEPTANCE-DATETIME>20060620114531
ACCESSION NUMBER:		0001130319-06-000498
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060620
FILED AS OF DATE:		20060620
DATE AS OF CHANGE:		20060620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		06914637

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o32049e6vk.htm
<DESCRIPTION>PRESS RELEASE DATED JUNE 20, 2006
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of June 2006

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Signatures</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: June 20, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o32049o3204900.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt"><B><HR align="left" size="1" width="100%" noshade></B>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><FONT face="Helvetica,Arial,sans-serif"><B>Oncolytics Biotech Inc. Completes Patient Enrolment in</B></FONT><BR>
<FONT face="Helvetica,Arial,sans-serif"><B>Phase Ia Combination REOLYSIN</B><SUP style="font-size: 85%; vertical-align: text-top"><B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></B></SUP><B>/Radiation Clinical Trial</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; June&nbsp;20, 2006 </B>&#150; Oncolytics Biotech Inc. (&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY) is
pleased to announce that it has completed patient enrolment in its Phase Ia U.K. clinical trial
investigating the use of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> in combination with radiation to treat patients with
advanced cancers. A total of 11 patients were treated in the Phase Ia trial with two intratumoural
treatments of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> </SUP>at dosages of 1x10<SUP style="font-size: 85%; vertical-align: text-top">8</SUP>,<SUP style="font-size: 85%; vertical-align: text-top">
</SUP>1x10<SUP style="font-size: 85%; vertical-align: text-top">9</SUP>,<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>or 1x10<SUP style="font-size: 85%; vertical-align: text-top">10 </SUP>TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50 </SUB>with a constant localized
radiation dose of 20 Gy in five fractions. A maximum tolerated dose (MTD)&nbsp;was not reached and the
combination treatment appears to have been well tolerated by the patients.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Interim results of the trial were presented at the American Association for Cancer Research (AACR)
Annual Meeting in Washington, D.C. in April&nbsp;2006. Preliminary analysis has demonstrated evidence
of local and systemic response.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Phase Ib portion of the trial, which will immediately follow the Phase Ia portion, will treat
patients with a range of two to six intratumoural doses of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> at
1x10<SUP style="font-size: 85%; vertical-align: text-top">10</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50</SUB> with a constant radiation dose of 36 Gy in 12 fractions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The primary objective of the trial is to determine the MTD, dose limiting toxicity (DLT), and
safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> when administered intratumourally to patients receiving
radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity.
Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
that are refractory (have not responded) to standard therapy or for which no curative standard
therapy exists.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The principal investigators for the trial are Dr.&nbsp;Kevin Harrington of the Targeted Therapy
Laboratory, The Institute of Cancer Research, Cancer Research UK Centre for Cell and Molecular
Biology and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust,
London, UK, and Dr.&nbsp;Alan Melcher of the Cancer Research U.K. Clinical Centre at St. James&#146;s
University Hospital in Leeds. The trial is enrolling patients at the Royal Marsden and St. James&#146;s
Hospitals in the U.K.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation. For further information about Oncolytics,
please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company&#146;s expectations related to the U.K. Phase Ia combination REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>/radiation
clinical trial, and the Company&#146;s belief as to the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer
therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#146;s
actual results to differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment, the tolerability
of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> outside a controlled test, the success and timely completion of clinical
studies and trials, the Company&#146;s ability to successfully commercialize REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>,
uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Company&#146;s quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking
statements.</I>
</DIV>



<P align="left" style="font-size: 10pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Cathy Ward</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Damian McIntosh</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">210, 1167 Kensington Cr NW</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Toronto Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11 Stone Street, 3rd Floor</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Calgary, Alberta T2N 1X7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toronto, Ontario M5C 2B8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10004</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Tel: 403.670.7377</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 416.815.0700 ext. 226</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Fax: 403.283.0858</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 416.815.0080</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>cathy.ward@oncolytics.ca</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>dmcintosh@investorrelationsgroup.com</U></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>www.oncolyticsbiotech.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">-30-

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o32049o3204900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o32049o3204900.gif
M1TE&.#EA\@`W`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#R`#<```C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6&*S)FO,BQH\>/($.*I&B%2R!6UZ#-NG8-):M`
M5E:,G$FSILV;%U><O!:-):M9UEK):GEM:,N8.),J7<J4XXJ?UJX)5<FJ5*"K
MK++V1#DTD,RF8,.*9>I2ZDLK"E=88=6*Z,NQ<./*O;C6+5*':HG.8O5UKM^_
M@`4&*AJ-%=J).EE!.QJXL>.F.HEZS8D(Y;7#CS-K%CDX*^:+)#I?WDRZ=$71
MGSNB-LVZM4(K1:_U!0E;5K39KG.;7A'-=FJ0@7JSTDW<-"O;@6RBC,:EN//'
M=5D9L!F#55#<S[/#13D+^\A`0)-K_Q\_%C:TX3A70&M+OCW8K+-^T^PLWKU]
MFT];+ETQ%/W]_R/5M@=9O0%H8$@[R5=3(+X=Z"!'+GE7DX`(77450E5<)6%!
M5IR4U5D;"J26AUG!%"(`.L'$4(<:)L3B9RQ:*..,V*6H($$C?HB(B@DE]F&)
M=QWD$F2S1',(0L<)=U`7*-V(HF4E[E24@FNY]%(@B*C$&$)UU:=09WP=-)@L
M_@F4E5MHEO5;EU]"N6,I9X;)(906PJ>2EP.MT%*92J7$YT"L]+:507IL*29+
MDQ6TD9@1&O145][!EI5#@^V%6V>F,-3H0I+^*:)+7>"V*(<^U:@60OQ=@V=2
M/WD*P'&7;?\JD!4K*>C2JISVIU`I;>%J15</!;*8G*^R=*2F0YT(P*^J'O24
M2D]`Q."D$?$F"ZXW68:D5``P6%A?YG5QT%I[2812*T[6=IM!5O26:;"V\179
M6PT%VMV*[AXZBQ[56AF3LB(6B:U-K5CCJF+7"&:-I;,V>>AYU<ZR6(C\];:F
M;<?"N^=*`QL$E;*_&GD040`;Y.$U*[%RR+\]+EP*6&8A"50`@D5CL$RUR3=F
MQ\ZB;`T+"I5`V)KY1K23=3P7I-B]G!:-8ZD5=7AF3RT=(N&03/%G,)(J]<5%
M6WQ5T9;.\59[WF@]VA8?NQA/M),@$?TDVXIM>XQ2#!ZIM5S"0K;_5/)'[<XR
M8-_0S%8;*RQ8$XU\UA)+Z9ZO]0;-`>P6]:[1+:T2-S2R@&RYOI=W]&@KWNWT
MMT>!%&SK+$P/U&Y+M7*YE9-]H^WHN8",&VC&$.TQ%-P0R0WR[@>5<,AB5N<=
MJ#61HLSO4M:U,AWAV-7%^8WDGF=%3-N79`KC.\'T;XZ&DDIF]^@'>1`7O;T<
M?-<K?EYAH-=NK];V+1+D4O=JC=B?@GJB5E)4@#)H).1,D9(;[:2V$K>88F4N
M.HG$)N@N+FRH+E1CB0;GEA`]%(EW]9+8\)K5HT"8HBPN.42B1(25#4+)%"OL
M6^MN<@7D*$0%"R%!M4;E$!)H9`4X?!"._S2"EXRPK"&_@AA.`J"XS@GQB161
M"O-P4IND0?&*)@N*JT#R%)2<#HM8W)]R$`7&,CJD+AP<"2"$LL4\H4@D/.S1
M&P$FDY+%T5D$T:'H&/)%$?7Q4"B9B14*MCA-&>8D/`L$"&\G/L.DI4/7XM'\
MKK*]A5"R0R%*XPPI\I00P48\:UF(C3K4$5@YKB.#7)@5S\*BA7`A=(Y*(P!L
MEQ!9SJ]["Z%7O<1G!6C0#B-\<Y%A^!+*A!B`EJ)CB]\`=XV@6/%57M%;B/:P
M2!PY4D2R@`)#2,<0#=VQ(!=RR&4TLDG$G))#LE@6*P#1QA)<DXMG0B9B1/-,
M:'8OANSBF4ZZMY*'7[X*9+QTT@JN`(CN!1%)?3FG1)["*?2L0!#Z#.AK%+HM
ME.`3(FM16SW-R%&3$4557^RB%/W9T9(Z2F*R*-@[2\B=/?W1I"8USUY\PLKM
MF80M05G8>5X*TYY&IX!`*5A;;";%5I0";SU-:D5&I)*<`J4W>S&14J?JE!]J
8I`14S:I6M\K5KGKUJV`-JUC'NM6````[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
